Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
stumble on this tweet.. looks like Leronlimab is on the radar.
https://twitter.com/KapilHandaMN/status/1288538767842738181?s=20
Yes, I suspect NP will announce 2b/3 filled with the addition of Baylor tomorrow.
Done adding more shares today, GLTA!
Since the last conference, NP had been pretty quiet.. no interviews or updates giving. If everyone listen in to the last conference.. NP stated that once the efficiency data is out, Cytodyn will immediate forward it to the FDA and request for emergency approval along with the 100 patients Phase 2b/3 DSMC progress (that's all the hints I needed). My guess is that NP had been informed by the legals to stay shut until reports are out (to avoid inside trading)... our Thursday conference is to confirm the efficiency endpoint and will be pushing for emergency approval, until then.. SP will not move much.
Here’s some CCR1 drugs that could combine with Leronlimab if the study is accurate.
https://www.eurekaselect.com/86440/article/ccr1-antagonists-what-have-we-learned-clinical-trials
The identification of chemokines and their receptors as potent mediators of leukocyte infiltration raised interest in the potential role of these proteins on disease pathogenesis. This is exemplified by the chemokine receptor, CCR1, which has been shown to be up-regulated in a number of human diseases, the implications of which have been suggested by animal models where inhibition of CCR1 or its ligands have shown beneficial effects. These data support the possibility that a CCR1 antagonist will provide therapeutic benefit to patients with inflammatory diseases. Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. This review will describe the evidence that supported the role of CCR1 in these diseases, the results from clinical trials, and provide perspectives on what has been learned from these trials for potential application / consideration to other studies with chemokine receptor antagonists.
Scientists identified a potential antibody cocktail for Covid-19
Count me in as well!!
It's great to see someone that's also wearing the same pants as I do, I got in to CYDY due to covid back when it was $3.5x in March, since then I've been building my holdings from $2.7x-$8.xx... even this morning @ $5.6 after I listened to the shareholder's meeting last night. Wifey couldn't understand why I'm so into CYDY and not others, after showing her BP's TED Talk and explaining the Phase 1 & 2 findings, she's now a believer of my investment.
Personally, I believe the science behind CYDY and the abilities to help many in needs. Who knows, maybe we can turn some shorties into long.. GLTA!!
Baylor University Medical Center Investigates Safety & Efficacy of Leronlimab in Severe to Critical COVID-19 Patients
https://www.trialsitenews.com/baylor-university-medical-center-investigates-safety-efficacy-of-leronlimab-in-severe-to-critical-covid-19-patients/
“Experimental treatment may bridge the gap”.. she’s referring to vaccines in terms of “As early as later this year”
Here’s the video from NBC FWT
Word is getting out, thanks for the post!
Not to mention most Bio stocks aren't doing too well today either. CYDY yet continue to hold with the short attack today, we are all also waiting for safety review by Data Safety Monitoring Committee (DSMC) for ongoing Phase 3 study (severe/critical population) sometime this or next week.. getting really close to FDA approval IMO.
Don’t forget Trump briefing today at 5PM, who knows.. maybe we get 100% stockpile buy out. I gotta give credit to CYDY’s PR, we’re all packed up this week as more positive news are gradually coming out. These roaches as I call the shorties.. roaches never dies but we sure will whip out a good portion of them.
I might of just bought your shares.. great news this morning and more coming!!
Let the stockpile begin!!!! NP and BP.. let’s rock the world!!!
Looking forward to Dr BP and Dr Been tonight and the un-blinding result tomorow!! GLTA!!
How about over $7?
What's your take? ..will we be closing over $6.50 today?
sh!t is about to get real!!
nice line up.. don't u think? hint.. hint!!
saw that too.. hint, hint!!
I had been doing it all this week.. cheers to all!!
maybe we'll see it close @ $10.01 today?
no clue why these shorts are bragging, long had been here for ages and the most these roches can short the stock is to $0.0001... too bad for them stock can't go negative. Long aren't looking at $5.06 or $5.60 gains, the more these roches shorts, the more I'm able to sweep up.
Looking forward to next week!!
must keep thanking these shorts, wasn't able to pick up more in the 3's 2 days ago.. got them at 4. I'll donate some coffin to these shorts to show my gratitude
My gut feeling shorts is going to start covering, as time is not on their side now. I was able to pick up another 10k shares at $4.70 thanks to them. Although my gut had been wrong before, if so I’ll be back for more.
This is what I'm seeing, are these intraday?
16:13:48 $6.09 250,000
16:13:48 $6.09 400,000
16:13:31 $6.99 250,000
16:13:28 $6.99 400,000
16:13:20 $6.99 400,000
16:13:20 $6.99 250,000
16:00:19 $5.93 1,000
Anyone Seeing the After Hour T-Trade? Similar to the 650k Shares made last week after close @ $6.38
4:02:16 @ $6.40 152,646 shares
4:18:27 @ $6:48 400,000 shares
4:18:27 @ $6.48 200,000 shares
HIV Cure Challenger CytoDyn Takes On Gilead Sciences
This may take us to the top!
https://talkmarkets.com/content/stocks--equities/hiv-cure-challenger-cytodyn-takes-on-the-gilead-sciences?post=267711
Sharing a post on another board
Ameritrade shows a couple of T-trades at 16:09:28, one for 225,000 and the other for 400,000 shares, both at $6.338